Active	Status	Sponsor type	Region	Phase	Filter
9 Active 18 Inactive 27 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

9 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ztalmy (ganaxolone oral) / Marinus
2021-003441-38: A trial for children and adults with Tuberous Sclerosis Complex (TSC)-related Epilepsy to determine how effective Ganaxolone treatment is.	Ongoing	3	200	Europe	Ganaxolone, Oral suspension	Marinus Pharmaceuticals Inc., Marinus Pharmaceuticals, Inc., Marinus Pharmaceuticals Inc., Marinus Pharmaceuticals, Inc.	Tuberous Sclerosis Complex (TSC)-related epilepsy, Seizures due to Tuberous Sclerosis Complex (TSC), Diseases [C] - Nervous System Diseases [C10]
TrustTSC, NCT05323734 / 2021-003441-38: Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy	Completed	3	128	Europe, Canada, US, RoW	Ganaxalone, Placebo	Marinus Pharmaceuticals, Marinus Pharmaceuticals Inc., Marinus Pharmaceuticals, Inc.	Tuberous Sclerosis Complex	09/24	10/24
NCT05249556: Double-blind, Randomized, Placebo-controlled Trial of Ganaxolone in CDKL5 Deficiency Patients 6 Months to Less Than 2 Years Old	Not yet recruiting	3	20	NA	Ganaxolone, Active Drug, Placebo, Inactive	Marinus Pharmaceuticals	CDKL5 Deficiency Disorder	12/26	03/27
NCT05604170: Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy	Enrolling by invitation	3	132	Europe, Canada, US, RoW	Ganaxolone	Marinus Pharmaceuticals	Tuberous Sclerosis Complex	06/27	06/27
NCT02766920: Augmentation of Treatment-Resistant Depression With An Analog of the Neuroactive Steroid Allopregnanolone	Not yet recruiting	N/A	10	US	CCD-1042	Massachusetts General Hospital	Major Depressive Disorder	08/18
CDD, NCT04678479: Ganaxolone Expanded Access Program Compassionate Use	No Longer Available	N/A		NA	Ganaxolone	Marinus Pharmaceuticals	CDKL5 Disorder
ganaxolone IV / Marinus
RAISE, NCT04391569: Randomized Therapy In Status Epilepticus	Completed	3	124	Canada, US, RoW	Ganaxolone, Placebo	Marinus Pharmaceuticals	Status Epilepticus	03/24	04/24
NCT05814523: To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE)	Withdrawn	3	70	Europe, RoW	Ganaxolone, Placebo, Standard of care	Marinus Pharmaceuticals	Refractory Status Epilepticus	08/24	08/24
NCT05757544: Safety and Efficacy Study of IV Ganaxolone as Adjuvant Therapy for Established Status Epilepticus (ESE)	Withdrawn	2	120	NA	IV Ganaxolone, IV Placebo	Marinus Pharmaceuticals	Status Epilepticus	02/26	02/26